Shots:

• Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines
• The companies are jointly developing AT-527 for the treatment of COVID-19 where Atea retains commercialization rights for AT-527 in the US and Roche holds the exclusive right to commercialize AT-527 outside of the US
• AT-527 is currently being evaluated in the global P-III MORNINGSKY trial- P-II study for hospitalized patients with moderate COVID-19- and a P-II outpatient study in patients with mild or moderate COVID-19

  Ref: Globe Newswire | Image: Roche